BioSpace News Archive

- Celularity has entered into a definitive merger agreement with GX Acquisition Corp. upon closing, shares of the combined company will be listed on Nasdaq under the ticker symbol “CELU”. - Institutional investors and certain individuals have committed to invest approximately $80 million through concurrent equity investments - $372 million of total expected proceeds from the PIPE and cash held in GX Acquisition

Significant 12-month overall survival benefit in the CPB7 population and 2 patients are still under treatment for more than 3.5 years Namodenoson is headed into a global pivotal Phase III study

Dr. Toralf Haag appointed to Supervisory Board and a member of the Audit Committee

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has agreed to acquire TransChart LLC, an Ohio-based provider of electronic health record software supporting the needs of US transplant centers. The transaction is expected to close in Ja

Loop-mediated isothermal amplification (LAMP) have risen in popularity for DNA amplification.

High prevalence of diabetes, overweight, and arthritis has significantly increased the demand for waterproof orthotics.

Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPID) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Company’s senior management will participate in two virtual investor conferences in January

Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors.